Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 7/2014

01-07-2014 | Original Article

Tumor hypoxia and microscopic diffusion capacity in brain tumors: A comparison of 62Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) PET/CT and diffusion-weighted MR imaging

Authors: Ayako Hino-Shishikura, Ukihide Tateishi, Hirofumi Shibata, Tomohiro Yoneyama, Toshiaki Nishii, Ikuo Torii, Kensuke Tateishi, Makoto Ohtake, Nobutaka Kawahara, Tomio Inoue

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2014

Login to get access

Abstract

Objectives

The aim of this study was to clarify the relationship between tumor hypoxia and microscopic diffusion capacity in primary brain tumors using 62Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) (62Cu-ATSM) PET/CT and diffusion-weighted MR imaging (DWI).

Methods

This study was approved by the institutional human research committee and was HIPAA compliant, and informed consent was obtained from all patients. 62Cu-ATSM PET/CT and DWI were performed in a total of 40 primary brain tumors of 34 patients with low grade glioma (LGG, n = 13), glioblastoma (GBM, n = 20), and primary central nervous system lymphoma (PCNSL, n = 7). 62Cu-ATSM PET/CT parameters and apparent diffusion coefficient (ADC) obtained by DWI were compared.

Results

High intensity signals by 62Cu-ATSM PET/CT and DWI in patients with GBM and PCNSL, and low intensity signals in LGG patients were observed. An inverse correlation was found between maximum SUV (SUVmax) and minimum ADC (ADCmin) (r = −0.583, p < 0.0001), and between tumor/brain ratio (T/Bratio) and ADCmin for all tumors (r = −0.532, p < 0.0001). Both SUVmax and T/Bratio in GBM were higher than LGG (p < 0.0001 and p < 0.0001), and those in PCNSL were also higher than GBM (p = 0.033 and p = 0.044). The ADCmin was lower in GBM (p = 0.011) and PCNSL (p = 0.01) than in LGG, while no significant difference was found between GBM and PCNSL (p = 0.90).

Conclusion

Tumor hypoxia assessed by 62Cu-ATSM PET/CT correlated with microscopic diffusion capacity obtained by DWI in brain tumors. Both 62Cu-ATSM PET/CT and DWI were considered feasible imaging methods for grading glioma. However, 62Cu-ATSM PET/CT provided additional diagnostic information to differentiate between GBM and PCNSL.
Literature
1.
Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996;379:88–91.PubMedCrossRef
2.
Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843–5.PubMedCrossRef
3.
Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol. 2009;92:317–35.PubMedCrossRef
4.
Le Bihan D, Breton E, Lallemand D, et al. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 1986;161:401–7.PubMed
5.
Warach S, Chien D, Li W, Ronthal M, et al. Fast magnetic resonance diffusion-weighted imaging of acute human stroke. Neurology. 1992;42:1717–23.PubMedCrossRef
6.
Pierpaoli C, Righini A, Linfante I, et al. Histopathologic correlates of abnormal water diffusion in cerebral ischemia: diffusion-weighted MR imaging and light and electron microscopic study. Radiology. 1993;189:439–48.PubMed
7.
Khayal IS, Vandenberg SR, Smith KJ, et al. MRI apparent diffusion coefficient reflects histopathologic subtype, axonal disruption, and tumor fraction in diffuse-type grade II gliomas. Neuro Oncol. 2011;13:1192–201.PubMedCentralPubMedCrossRef
8.
Murakami R, Hirai T, Sugahara T, et al. Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method. Radiology. 2009;251:838–45.PubMedCrossRef
9.
Barajas Jr RF, Rubenstein JL, Chang JS, et al. Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. Am J Neuroradiol. 2010;31:60–6.PubMedCentralPubMedCrossRef
10.
Higano S, Yun X, Kumabe T, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology. 2006;241:839–46.PubMedCrossRef
11.
Hoigebazar L, Jeong JM. Hypoxia imaging agents labeled with positron emitters. Recent results. Cancer Res. 2012;194:285–99.
12.
Fujibayashi Y, Taniuchi H, Yonekura Y, et al. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155–60.PubMed
13.
Imam SK. Review of positron emission tomography tracers for imaging of tumor hypoxia. Cancer Biother Radiopharm. 2010;25:365–74.PubMedCrossRef
14.
Wen B, Burgman P, Zanzonico P, et al. A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia. Eur J Nucl Med Mol Imaging. 2004;31:1530–8.PubMedCrossRef
15.
Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 1995;22:265–80.PubMedCrossRef
16.
Martin GV, Caldwell JH, Graham MM, et al. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med. 1992;33:2202–8.PubMed
17.
Sheehan JP, Popp B, Monteith S, et al. Trans sodium crocetinate: functional neuroimaging studies in a hypoxic brain tumor. J Neurosurg. 2011;115:749–53.PubMedCrossRef
18.
Lewis JS, Sharp TL, Laforest R, et al. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med. 2001;42:655–61.PubMed
19.
Tateishi K, Tateishi U, Sato M, et al. Application of 62Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1alpha expression in patients with glioma. Am J Neuroradiol. 2012;34:92–9.PubMedCrossRef
20.
Brat DJ, Van Meir EG. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest. 2004;84:397–405.PubMedCrossRef
21.
22.
Fujibayashi Y, Cutler CS, Anderson CJ, et al. Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nucl Med Biol. 1999;26:117–21.PubMedCrossRef
23.
Read SJ, Jackson GD, Abbott DF, et al. Experience with diffusion-weighted imaging in an acute stroke unit. Cerebrovasc Dis. 1998;8:135–43.PubMedCrossRef
24.
Lewis JS, McCarthy DW, Welch MJ, et al. Evaluation of 64Cu-ATSM in vitro and in vivo in a tumor model. J Nucl Med. 1999;40:177–83.PubMed
25.
Yuan H, Schroeder T, Bowsher JE, Dewhirst MW, et al. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2006;47:989–98.PubMed
26.
Schlegel U, Schmidt-Wolf IG, Deckert M. Primary CNS lymphoma: clinical presentation, pathological classification, molecular pathogenesis and treatment. J Neurol Sci. 2000;181:1–12.PubMedCrossRef
27.
28.
Guo AC, Cummings TJ, Dash RC, et al. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology. 2002;224:177–83.PubMedCrossRef
29.
Matsushima N, Maeda M, Umino M, et al. Relation between FDG uptake and apparent diffusion coefficients in glioma and malignant lymphoma. Ann Nucl Med. 2012;26:262–71.PubMedCrossRef
30.
Buchbender C, Heusner TA, Lauenstein C, et al. Oncologic PET/MRI, Part 1: tumor of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med. 2012;53:928–38.PubMedCrossRef
31.
Buchbender C, Heusner TA, Lauenstein C, et al. Oncologic PET/MRI, Part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med. 2012;53:1244–52.PubMedCrossRef
Metadata
Title
Tumor hypoxia and microscopic diffusion capacity in brain tumors: A comparison of 62Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) PET/CT and diffusion-weighted MR imaging
Authors
Ayako Hino-Shishikura
Ukihide Tateishi
Hirofumi Shibata
Tomohiro Yoneyama
Toshiaki Nishii
Ikuo Torii
Kensuke Tateishi
Makoto Ohtake
Nobutaka Kawahara
Tomio Inoue
Publication date
01-07-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-014-2714-x

Other articles of this Issue 7/2014

European Journal of Nuclear Medicine and Molecular Imaging 7/2014 Go to the issue

Original Article

11C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients

Original Article

Combined SPECT/CT improves detection of initial bone invasion and determination of resection margins in squamous cell carcinoma of the head and neck compared to conventional imaging modalities

Editorial Commentary

PET/CT imaging and the oligometastatic prostate cancer patient: an opportunity for a curative approach with high-dose radiotherapy?

Original Article

PET imaging of neuroinflammation in a rat traumatic brain injury model with radiolabeled TSPO ligand DPA-714

Original Article

Treatment outcomes of patients with cervical cancer with complete metabolic responses after definitive chemoradiotherapy

Original Article

Insight on AV-45 binding in white and grey matter from histogram analysis: a study on early Alzheimer’s disease patients and healthy subjects